James E Herndon Selected Research

Monoclonal Antibodies

8/2012	Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
1/2012	A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
1/2012	Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
9/2011	Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
4/2011	A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.
11/2008	Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
4/2008	A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
5/2007	Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
6/2006	Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
1/2006	Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James E Herndon Research Topics

Disease

121	Neoplasms (Cancer) 01/2024 - 01/2002
60	Glioma (Gliomas) 01/2023 - 03/2002
52	Glioblastoma (Glioblastoma Multiforme) 01/2023 - 01/2004
26	Leukemia 09/2019 - 01/2002
20	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017 - 01/2002
19	Brain Neoplasms (Brain Tumor) 01/2022 - 10/2003
16	Breast Neoplasms (Breast Cancer) 12/2023 - 08/2003
12	Lung Neoplasms (Lung Cancer) 01/2023 - 06/2004
11	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2008 - 02/2002
9	Fatigue 04/2022 - 10/2010
8	Chronic Disease (Chronic Diseases) 04/2022 - 12/2008
7	Neoplasm Metastasis (Metastasis) 01/2023 - 03/2002
6	Nausea 12/2020 - 03/2008
6	Vomiting 12/2020 - 03/2008
6	Lymphopenia (Lymphocytopenia) 01/2018 - 03/2011
6	Dyspnea (Shortness of Breath) 10/2015 - 04/2005
5	Melanoma (Melanoma, Malignant) 01/2013 - 04/2006
4	Disease Progression 04/2019 - 07/2002
4	Diarrhea 07/2012 - 01/2004
4	Hypoxia (Hypoxemia) 04/2011 - 01/2008
4	Weight Loss (Weight Reduction) 09/2009 - 01/2006
4	Neutropenia 06/2009 - 01/2006
3	Necrosis 01/2024 - 10/2017
3	Infections 01/2023 - 03/2008
3	Medulloblastoma 01/2023 - 12/2004
3	Meningioma (Meningiomas) 05/2022 - 01/2012
3	Astrocytoma (Pilocytic Astrocytoma) 01/2019 - 01/2006
3	Thrombocytopenia (Thrombopenia) 03/2012 - 10/2002
3	Carcinogenesis 09/2011 - 04/2005
3	Colorectal Neoplasms (Colorectal Cancer) 01/2010 - 03/2006
3	Febrile Neutropenia 06/2009 - 01/2006
3	Malignant Mesothelioma 06/2005 - 05/2004
3	Carcinoma (Carcinomatosis) 11/2004 - 01/2002
2	Inflammation (Inflammations) 01/2023 - 12/2018
2	Poliomyelitis (Polio) 01/2023 - 01/2021
2	Lymphoma (Lymphomas) 04/2020 - 08/2013
2	Residual Neoplasm 09/2018 - 11/2010

Drug/Important Bio-Agent (IBA)

30	Temozolomide (Temodar)FDA LinkGeneric 12/2020 - 02/2003
24	Bevacizumab (Avastin)FDA Link 01/2023 - 02/2007
20	Irinotecan (Camptosar)FDA LinkGeneric 04/2019 - 04/2004
19	ErbB Receptors (EGF Receptor)IBA 01/2023 - 01/2004
17	epidermal growth factor receptor VIIIIBA 01/2023 - 01/2008
11	VaccinesIBA 10/2020 - 11/2008
11	AntigensIBA 01/2018 - 04/2006
11	Monoclonal AntibodiesIBA 08/2012 - 03/2002
9	Carboplatin (JM8)FDA LinkGeneric 03/2012 - 07/2002
9	Paclitaxel (Taxol)FDA LinkGeneric 11/2008 - 02/2002
8	Proteins (Proteins, Gene)FDA Link 01/2023 - 12/2004
7	Cisplatin (Platino)FDA LinkGeneric 11/2008 - 01/2002
6	Biomarkers (Surrogate Marker)IBA 04/2015 - 12/2004
6	Imatinib Mesylate (Gleevec)FDA Link 10/2012 - 12/2005
6	Tyrosine Kinase InhibitorsIBA 07/2012 - 01/2004
6	O(6)-benzylguanineIBA 10/2009 - 05/2002
5	Messenger RNA (mRNA)IBA 01/2023 - 03/2002
5	Chimeric Antigen ReceptorsIBA 01/2019 - 01/2014
5	Hydroxyurea (Hydrea)FDA LinkGeneric 10/2012 - 12/2005
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2012 - 01/2008
4	7- chloro- 8- hydroxy- 1- (3'- iodophenyl)- 3- methyl- 2,3,4,5- tetrahydro- 1H- 3- benzazepine (TISCH)IBA 06/2021 - 07/2014
4	AntiemeticsIBA 05/2020 - 07/2014
4	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2014 - 02/2004
4	Immunotoxins (Immunotoxin)IBA 07/2011 - 01/2008
4	Etoposide (VP 16)FDA LinkGeneric 06/2011 - 02/2005
4	Carmustine (FIVB)FDA Link 08/2009 - 05/2002
4	Vinorelbine (Navelbine)FDA LinkGeneric 06/2007 - 10/2002
3	Ondansetron (Zofran)FDA LinkGeneric 12/2020 - 01/2017
3	Dasatinib (BMS 354825)FDA Link 01/2020 - 07/2012
3	Adenosine Triphosphate (ATP)IBA 01/2020 - 12/2005
3	EnzymesIBA 01/2019 - 04/2005
3	MethyltransferasesIBA 01/2019 - 10/2005
3	Palonosetron (Aloxi)FDA Link 01/2017 - 07/2014
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2012 - 01/2010
3	O(6)-Methylguanine-DNA MethyltransferaseIBA 12/2009 - 05/2002
3	TabletsIBA 06/2009 - 12/2008
3	Gefitinib (Iressa)FDA Link 02/2006 - 01/2004
3	Topoisomerase I InhibitorsIBA 10/2005 - 04/2004
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2023 - 03/2005
2	RNA (Ribonucleic Acid)IBA 01/2023 - 03/2015
2	Phosphotransferases (Kinase)IBA 01/2023 - 06/2008
2	poliovirus receptorIBA 01/2023 - 12/2018
2	Aprepitant (Emend)FDA Link 12/2020 - 05/2020
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020 - 07/2014
2	Interleukin-2 (IL2)IBA 01/2019 - 01/2012
2	Vorinostat FDA Link 04/2018 - 01/2018
2	Single-Chain AntibodiesIBA 01/2018 - 07/2011
2	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2018 - 03/2014
2	Oxygen (Dioxygen)IBA 10/2015 - 09/2010
2	Clostridium perfringens epsilon-toxinIBA 02/2015 - 01/2014
2	Alkylating AgentsIBA 08/2013 - 01/2013

Therapy/Procedure

72	Therapeutics 01/2024 - 01/2002
43	Drug Therapy (Chemotherapy) 12/2023 - 01/2002
26	Radiotherapy 05/2022 - 10/2002
15	Immunotherapy 01/2023 - 11/2008
6	Induction Chemotherapy 09/2009 - 10/2002
5	Adjuvant Chemotherapy 12/2023 - 08/2003
5	Catheters 01/2023 - 07/2002
5	Salvage Therapy 05/2022 - 09/2004
4	Chemoradiotherapy 01/2011 - 10/2002
3	Lasers (Laser) 01/2024 - 01/2022
3	Exercise Therapy (Therapy, Exercise) 12/2023 - 01/2020
3	Aftercare (After-Treatment) 10/2017 - 08/2003